Decision: Favourable

Study Title:

A Phase 3, Randomized, Multicentre, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Participants with Light Chain (AL) Amyloidosis

  • NREC Code:


  • Decision:


  • Meeting Date:


  • Study Type:

    CT application

  • Principal Investigator:

    Dr John Quinn

  • PI Institution:

    Beaumont Hospital

  • Sponsor:

    Prothena Biosciences Limited

Scroll to Top